

Form PTO-1449

Sheet 1 of 3

Applicant: Peter M. Allred et al.

Serial No.: 10/728,525

Att'y Docket No.: 7678.816.1

Filing Date: December 5, 2003

Group: 3732

For: Treatment compositions and strips having a solid adhesive layer and treatment gel adjacent thereto

INFORMATION DISCLOSURE CITATIONS MADE BY APPLICANT**U.S. Patent Documents**

Examiner Initial*	Patent Number	Issue Date	Name	Class	Sub Class	Filing Date
<u>CEO</u> A1.	165,584	07/13/1875	Hopfen	--	--	06/10/1875
<u>CEO</u> A2.	1,637,153	07/26/27	Lawton	--	--	10/23/26
<u>CEO</u> A3.	2,257,709	09/30/41	Anderson	128	260	10/14/38
<u>CEO</u> A4.	3,339,547	09/05/67	Drabkowski	128	260	11/27/64
<u>CEO</u> A5.	3,527,219	09/08/70	Greenberg	128	260	08/21/67
<u>CEO</u> A6.	3,577,640	05/04/71	Lee	32	32	10/08/69
<u>CEO</u> A7.	3,624,909	12/07/71	Greenberg	32	40	05/26/70
<u>CEO</u> A8.	3,955,281	05/11/76	Weitzman	32	14 B	12/05/74
<u>CEO</u> A9.	4,044,762	08/30/77	Jacobs	128	136	08/23/76
<u>CEO</u> A10.	4,063,552	12/20/77	Going et al.	128	136	04/02/76
<u>CEO</u> A11.	4,064,628	12/27/77	Weitzman	32	14 B	03/08/76
<u>CEO</u> A12.	4,138,814	02/13/79	Weitzman	32	14 B	12/22/77
<u>CEO</u> A13.	4,902,227	02/20/90	Smith	433	215	05/04/88
<u>CEO</u> A14.	5,051,476	09/24/91	Uji et al.	525	186	03/23/90
<u>CEO</u> A15.	5,085,585	02/04/92	Zimble	433	80	02/05/91
<u>CEO</u> A16.	5,211,559	05/18/93	Hart et al.	433	80	06/02/92
<u>CEO</u> A17.	5,356,291	10/18/94	Darnell	433	216	01/26/93

Examiner:

Cary E. O'Connor

Date Considered:

6/6/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

Sheet 2 of 3

Applicant: Peter M. Allred et al.

Serial No.: 10/728,525

Att'y Docket No.: 7678.816.1

Filing Date: December 5, 2003

Group: 3732

For: Treatment compositions and strips having a solid adhesive layer and treatment gel adjacent thereto

<u>CEO</u> A18.	5,376,006	12/27/94	Fischer	433	215	09/24/92
<u>CEO</u> A19.	5,573,399	11/12/96	McClintock, II	433	80	10/24/94
<u>CEO</u> A20.	5,631,000	05/20/97	Pellico	424	53	03/11/96
<u>CEO</u> A21.	5,702,251	12/30/97	McClintock, II	433	80	05/31/96
<u>CEO</u> A22.	5,752,826	05/16/96	Andreiko	433	41	05/19/98
<u>CEO</u> A23.	5,851,512	12/22/98	Fischer	424	49	05/30/97
<u>CEO</u> A24.	5,895,218	04/20/99	Quinn et al.	433	80	08/10/98
<u>CEO</u> A25.	5,985,249	11/16/99	Fischer	424	49	10/14/97
<u>CEO</u> A26.	6,089,869	07/18/00	Schwartz	433	215	03/15/99
<u>CEO</u> A27.	6,309,625	10/30/01	Jensen et al.	424	49	11/12/98
<u>CEO</u> A28.	6,312,671	11/06/01	Jensen et al.	424	53	12/20/99
<u>CEO</u> A29.	6,364,665	04/02/02	Trettemer	433	215	04/04/00
<u>CEO</u> A30.	6,379,147	04/30/02	Georgakidis et al.	433	37	06/26/00

Foreign Patent Documents

<u>Examiner</u>	<u>Document No.</u>	<u>Publication Date</u>	<u>Country or Pat Office</u>
<u>CEO</u> A31.	WO 03/000216	3 Jan 2003	WIPO
<u>CEO</u> A32.	WO 88/06869	22 September 1988	WIPO

References Cited by Applicants

While the filing of Information Disclosure Statements is voluntary, the procedure is governed by the guidelines of Section 609 of the Manual of Patent Examining Procedure and 37 C.F.R. §§ 1.97 and 1.98. To be considered a proper Information Disclosure Statement, Form PTO-1449 shall be accompanied by a copy of each listed patent or publication or other item of information and a translation of the pertinent portions of foreign documents (if an existing translation is readily available to the applicant), an explanation of relevance

Examiner: Cary E O'ConnorDate Considered: 6/6/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

Sheet 3 of 3

Applicant: Peter M. Allred et al.

Serial No.: 10/728,525

Atty Docket No.: 7678.816.1

Filing Date: December 5, 2003

Group: 3732

For: Treatment compositions and strips having a solid adhesive layer and treatment gel adjacent thereto

of each reference not in the English language, and should be submitted in a timely manner as set out in MPEP Sec. 609.

Examiners will consider all citations submitted in conformance with 37 C.F.R. § 1.98 and MPEP Sec. 609 and place their initials adjacent the citations in the spaces provided on this form. Examiners will also initial citations not in conformance with the guidelines which may have been considered. A reference may be considered by the Examiner for any reason whether or not the citation is in full conformance with the guidelines. A line will be drawn through a citation if it is not in conformance with the guidelines AND has not been considered. A copy of the submitted form, as reviewed by the Examiner, will be returned to the applicant with the next communication. The original of the form will be entered into the application file.

Each citation initialed by the Examiner will be printed on the issued patent in the same manner as references cited by the Examiner on Form PTO-892.

The reference designations "A1," "A2," etc. (referring to Applicant's reference 1, Applicant's reference 2, etc.) will be used by the Examiner in the same manner as Examiner's reference designations "A," "B," "C," etc. on Office Action Form PTO-1142.

re0000003886V001

Examiner:

Cary E O'Connor

Date Considered:

6/6/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.